ASPC Seeks 12-Month Extension, Waives Sponsor Contribution

TL;DR

**ASPC is pushing its deadline without sponsor cash, so redeem now or risk getting less later if the Bioserica deal falls through.**

AI Summary

ASPAC III Acquisition Corp. (ASPC) is seeking shareholder approval to extend its business combination deadline by 12 months, from November 12, 2025, to November 12, 2026. This extension is crucial as the company has already entered into a Merger Agreement with Bioserica International Limited on May 23, 2025, but anticipates insufficient time to close by the current deadline. A key change in the proposed Amended Charter is that it will *not* require the sponsor, A SPAC III (Holdings) Corp., to deposit additional funds into the Trust Account for this extension, unlike the current Charter which would require $600,000 for a three-month extension or $1,200,000 for six months. This means shareholders who do not redeem now would receive significantly less in a subsequent redemption or liquidation under the Amended Charter. As of October 6, 2025, the Trust Account held approximately $62.3 million, and the redemption price per share is estimated at $10.38. The Board unanimously recommends voting 'FOR' the Charter Amendment Proposal and the Adjournment Proposal.

Why It Matters

This extension is critical for ASPC to complete its proposed merger with Bioserica International Limited, preventing a potential liquidation that would return approximately $10.38 per share to public shareholders. The waiver of the sponsor's contribution for the extension, a departure from the original charter, shifts financial risk more directly to remaining public shareholders, potentially reducing their future redemption value. This move could set a precedent for other SPACs facing similar deadline pressures, impacting investor expectations for sponsor commitment and trust account integrity in a competitive de-SPAC market. Investors must weigh the potential upside of the Bioserica merger against the immediate dilution risk and the sponsor's reduced financial obligation.

Risk Assessment

Risk Level: high — The risk level is high because the proposed Charter Amendment explicitly states, 'CONTRARY TO THE TERMS OF THE CURRENT CHARTER, THE AMENDED CHARTER WILL NOT REQUIRE ADDITIONAL FUNDS TO BE DEPOSITED INTO THE TRUST ACCOUNT IF THE CHARTER AMENDMENT PROPOSAL IS APPROVED.' This means shareholders who elect not to redeem now will receive 'SIGNIFICANTLY LESS FROM ANY SUBSEQUENT REDEMPTION OR LIQUIDATION UNDER THE AMENDED CHARTER' compared to the current charter, which would require $600,000 for a three-month extension or $1,200,000 for six months. The sponsor, A SPAC III (Holdings) Corp., 'does not currently plan to contribute any funds' for the extension.

Analyst Insight

Investors should carefully consider exercising their redemption rights by October 23, 2025, to receive approximately $10.38 per share from the Trust Account. If the Charter Amendment passes, remaining shareholders will bear the full risk of the extended period without additional sponsor capital, potentially diminishing future redemption value if the Bioserica merger fails.

Key Numbers

• $62.3 million — Trust Account balance (As of October 6, 2025, available for redemptions.)
• $10.38 — Estimated redemption price per share (If the Charter Amendment is approved and the Combination Period is extended to November 12, 2026, without additional funds.)
• 12 months — Proposed extension period (From November 12, 2025, to November 12, 2026.)
• $600,000 — Cost for 3-month extension under current Charter (Sponsor would be required to deposit this amount for each 3-month extension.)
• 1,500,000 — Founder Shares (Owned by the Sponsor, which will become worthless if a business combination is not completed.)
• 285,000 — Private Placement Units (Owned by the Sponsor, which will become worthless if a business combination is not completed.)
• October 23, 2025 — Redemption deadline (Two business days prior to the Extraordinary General Meeting.)
• October 27, 2025 — Extraordinary General Meeting date (Date shareholders will vote on the extension.)
• May 23, 2025 — Merger Agreement date (Date ASPC entered into an agreement with Bioserica International Limited.)
• November 12, 2025 — Current Termination Date (Original deadline for ASPC to complete a business combination.)

Key Players & Entities

• ASPAC III Acquisition Corp. (company) — Registrant and SPAC seeking extension
• Bioserica International Limited (company) — Target company in the proposed Business Combination
• A SPAC III (Holdings) Corp. (company) — Sponsor of ASPAC III Acquisition Corp.
• Claudius Tsang (person) — Chief Executive Officer, Chief Financial Officer, and Chairman of ASPAC III Acquisition Corp.
• Loeb & Loeb LLP (company) — Location of the Extraordinary General Meeting
• China Securities Regulatory Commission (regulator) — Regulatory body whose filings are required for the Business Combination
• U.S. Securities and Exchange Commission (regulator) — Regulatory body whose filings are required for the Business Combination
• Registry of Corporate Affairs of the British Virgin Islands (regulator) — Body responsible for registering the Amended Charter
• Continental (company) — Transfer agent for ASPAC III Acquisition Corp.
• Depository Trust Company (company) — System for electronic share delivery (DWAC)

FAQ

Risk Factors

• Dilution of Trust Account Value for Non-Redeeming Shareholders [high — financial]: If the Charter Amendment is approved, the sponsor will not be required to deposit funds into the Trust Account for extensions. This means that if shareholders do not redeem their shares, they will receive a significantly lower per-share redemption or liquidation value in the future compared to the current charter terms. The Trust Account balance is $62.3 million as of October 6, 2025, with an estimated redemption price of $10.38 per share.
• Failure to Complete Business Combination [high — operational]: ASPC has entered into a Merger Agreement with Bioserica International Limited on May 23, 2025, but anticipates insufficient time to close by the current deadline of November 12, 2025. If the Charter Amendment is not approved and no business combination is completed by the Current Termination Date, ASPC will cease operations, redeem 100% of public shares from the Trust Account, and liquidate. The sponsor's founder shares (1,500,000) and private placement units (285,000) would become worthless.
• Regulatory Approvals for Business Combination [medium — regulatory]: The completion of the business combination with Bioserica International Limited is contingent on necessary filings and approvals from regulatory bodies, including the China Securities Regulatory Commission and the U.S. Securities and Exchange Commission. Delays or failures in obtaining these approvals could prevent the transaction from closing within the extended timeframe.
• Potential for High Shareholder Redemptions [medium — financial]: The company expects significant redemptions at the Extraordinary General Meeting on October 27, 2025. High redemption rates could deplete the Trust Account, potentially impacting the feasibility or terms of the proposed business combination with Bioserica.

Industry Context

ASPC operates within the Special Purpose Acquisition Company (SPAC) industry, which facilitates the listing of private companies on public exchanges through a merger. The current environment for SPACs has seen increased scrutiny and a slowdown in deal completions, making extensions and regulatory hurdles more common. Companies like ASPC face pressure to identify and close viable business combinations within strict timeframes.

Regulatory Implications

The proposed Charter Amendment and subsequent business combination are subject to regulatory review by bodies such as the China Securities Regulatory Commission and the U.S. SEC. Any delays or adverse findings in these reviews could jeopardize the transaction. Furthermore, changes to the company's charter and the structure of the business combination must comply with British Virgin Islands corporate law.

What Investors Should Do

1. Review the Proxy Statement carefully regarding the Charter Amendment Proposal.
2. Decide whether to redeem shares before the Extraordinary General Meeting.
3. Vote on the Charter Amendment Proposal and Adjournment Proposal.
4. Monitor the progress of the business combination with Bioserica International Limited.

Key Dates

• 2025-10-27: Extraordinary General Meeting — Shareholders will vote on the Charter Amendment Proposal to extend the business combination deadline and the Adjournment Proposal.
• 2025-10-23: Redemption Deadline — Shareholders must elect to redeem their shares at least two business days prior to the Extraordinary General Meeting.
• 2025-11-12: Current Termination Date — Original deadline for ASPC to complete a business combination. If not extended, the company will liquidate.
• 2026-11-12: Proposed Extended Termination Date — New deadline for ASPC to complete a business combination if the Charter Amendment is approved.
• 2025-05-23: Merger Agreement Date — ASPC entered into a Merger Agreement with Bioserica International Limited, outlining the terms of the proposed business combination.
• 2025-10-10: Mailing of Proxy Materials — Shareholders are first mailed the proxy statement and notice of the Extraordinary General Meeting.

Glossary

Trust Account

An account holding the proceeds from the company's Initial Public Offering (IPO), typically used to fund a business combination or returned to shareholders upon liquidation. (Contains the $62.3 million available for redemptions and will be distributed to shareholders if the business combination is not completed.)

Charter Amendment

A proposed change to the company's governing documents (Articles of Association) to extend the deadline for completing a business combination. (The primary proposal at the Extraordinary General Meeting, seeking to extend the company's life by 12 months.)

Redemption Price

The price per share at which shareholders can redeem their shares, typically their pro-rata portion of the Trust Account. (Estimated at $10.38 per share, but this value will be significantly reduced for non-redeeming shareholders if the sponsor is not required to fund extensions.)

Sponsor

The entity that initially organized the SPAC and typically receives founder shares and private placement units. (A SPAC III (Holdings) Corp. is the sponsor and is not required to deposit funds for this extension, impacting the value for non-redeeming shareholders.)

Business Combination

The acquisition or merger of the SPAC with a target company. (ASPC has entered into a Merger Agreement with Bioserica International Limited, but needs more time to complete this transaction.)

Public Shares

Ordinary shares issued in the company's IPO to the public. (These are the shares held by most shareholders, eligible for redemption and subject to dilution if the Charter Amendment passes without sponsor funding.)

Year-Over-Year Comparison

This filing is a proxy statement for an Extraordinary General Meeting, not a comprehensive annual or quarterly report, and therefore does not contain comparative financial statements or metrics like revenue, net income, or margins from a previous year. The primary focus is on the proposed extension of the business combination deadline and the associated changes to the company's charter, highlighting a shift in sponsor funding obligations for extensions and the potential impact on shareholder redemption values.

Key Financial Figures

• $600,000 — O (the “ Trust Account ”) $600,000 (i.e., $0.10 per issued and outstanding
• $0.10 — Trust Account ”) $600,000 (i.e., $0.10 per issued and outstanding share of Cla
• $1,200,000 — TO EXTEND OUR LIFE FOR THREE MONTHS, OR $1,200,000 FOR SIX MONTHS. THEREFORE, SHARE
• $100,000 — , including interest income (less up to $100,000 of interest to pay dissolution expenses
• $62.3 million — Trust Account, which held approximately $62.3 million as of October 6, 2025. In addition, pub
• $10.38 — n, as applicable, will be approximately $10.38 per share (without taking into account

Filing Documents

• ea0258566-02.htm (DEF 14A) — 734KB
• togier_001.jpg (GRAPHIC) — 16KB
• 0001213900-25-097917.txt ( ) — 757KB

From the Filing

DEF 14A 1 ea0258566-02.htm PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________ SCHEDULE 14A _________________________________ (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant   Filed by a Party other than the Registrant   Check the appropriate box:   Preliminary Proxy Statement   Confidential, for the use of the Commission only (as permitted by Rule 14a -6 (e)(2))   Definitive Proxy Statement   Definitive Additional Materials   Soliciting Material Pursuant to §240.14a -12 A SPAC III Acquisition Corp. (Name of Registrant as Specified in its Charter) _________________________________________________________________ (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box):   No fee required.   Fee paid previously with preliminary materials.   Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a -6 (i)(1) and 0 -11 .   A SPAC III ACQUISITION CORP. The Sun’s Group Center, 29 th Floor 200 Gloucester Road Wan Chai, Hong Kong October 10, 2025 Dear Shareholders: On behalf of the Board of Directors of A SPAC III Acquisition Corp. (the “ Company ,” “ ASPC ”, “ A SPAC III ” or “ we ”), I invite you to attend our Extraordinary General Meeting of Shareholders at 10 a.m. Eastern Time on October 27, 2025 (the “ Extraordinary General Meeting ”). We hope you can join us and participate by virtual attendance or in person. ASPC will be holding the Extraordinary General Meeting at the offices of Loeb & Loeb LLP, 345 Park Avenue, New York, NY 10154, and virtually via https://loeb.zoom.us/ j/97571650802?pwd=eLVp5OhlTmMNXwaBAjaza0p0oykqPC.1 . The Notice of Extraordinary General Meeting of Shareholders, the Proxy Statement and the proxy card accompanying this letter are also available at https: // www.cstproxy.com / aspaciiiacquisition/2025 . We are first mailing these materials to our shareholders on or about October 10, 2025. As discussed in the enclosed Proxy Statement, the Extraordinary General Meeting will be devoted to: (i)       a proposal to amend and restate (the “ Charter Amendment ”) the Company’s current amended and restated memorandum and articles of association (the “ Charter ”) to extend the date by which it has to consummate a business combination (the “ Extension ”) for an additional twelve months from November 12, 2025 (the “ Current Termination Date ”) to November 12, 2026 (the termination date as so extended, the “ Extended Termination Date ”) by deleting the Charter in its entirety and substituting it by the adoption of the amended and restated memorandum and articles of association in the form set forth in Annex A to the accompanying Proxy Statement (the “ Amended Charter ”), subject to registration of it by the Registry of Corporate Affairs of the British Virgin Islands (we refer to this proposal as the “ Charter Amendment Proposal ”); and (ii)      a proposal to adjourn the Extraordinary General Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the Extraordinary General Meeting, there are insufficient votes to approve the Charter Amendment Proposal (we refer to this proposal as the “ Adjournment Proposal ”). The purpose of the Charter Amendment and if necessary, the Adjournment Proposal, is to allow the Company additional time to complete a business combination (the “ Combination Period ”). Pursuant to the Company’s current Charter, the Company has the right to extend the Combination Period two (2) times for an additional three (3) months each time from November 12, 2025 (i.e., 12 months from the closing of the initial public offering (the “ IPO ”) up to May 12, 2026 (i.e., 18 months from the closing of the IPO). The only way to extend the Combination Period from November 12, 2025 without the need for a separate shareholder vote under the Charter is for our initial shareholders or their affiliates or designees, upon two days’ advance notice prior to the applicable de

View Full Filing

View this DEF 14A filing on SEC EDGAR